EE526 Cost-Effectiveness Analysis of Transthyretin-Associated Amyloid Cardiomyopathy from the Brazilian Public Healthcare System Perspective

Abstract

Transthyretin-associated amyloid cardiomyopathy (ATTR-CM) is a rare condition, caused by cardiac infiltration of amyloid fibrils, leading to organ dysfunction and, consequently, progressive heart failure. The hereditary form of the disease usually manifests itself after 47 years of age, with a median survival of 2.5 years after diagnosis for patients without treatment. The wild form affects almost exclusively older people, with a mean age at diagnosis of 74 years and a median survival from diagnosis in untreated patients of approximately 3.5 years (depending on the stage of the disease). The aim of this analysis is to compare utility and incremental costs between tafamidis and symptomatic treatment.